AngioDynamics (STU:UG2) 5-Year RORE % : 1.87% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UG2 AngioDynamics Inc STU:UG2
66 GF Score
Price €11.80
GF Value €8.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AngioDynamics 5-Year RORE %?

AngioDynamics STU:UG2 -3.28% 66 5-Year RORE % is 1.87 as of May. 2026. GuruFocus rates STU:UG2 with a GF Score™ of 66/100 and a GF Value™ of €8.32 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 702 Medical Devices & Instruments companies, AngioDynamics ranks better than 58.97% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. AngioDynamics's 5-Year RORE % for the quarter that ended in May. 2026 was 1.87%.

The industry rank for AngioDynamics's 5-Year RORE % or its related term are showing as below:

STU:UG2's 5-Year RORE % is ranked better than
58.97% of 702 companies
in the Medical Devices & Instruments industry
Industry Median: -5.13 vs STU:UG2: 1.87

AngioDynamics  (STU:UG2) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


AngioDynamics 5-Year RORE % Related Terms


AngioDynamics 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for AngioDynamics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics 5-Year RORE % Chart

AngioDynamics Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.70 52.94 2.38 1.13 1.87

AngioDynamics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 -0.43 -3.10 -2.88 1.87

STU:UG2 vs NNNN, OSUR, UTMD: 5-Year RORE % Comparison

For the Medical Instruments & Supplies subindustry, AngioDynamics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics 5-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where AngioDynamics's 5-Year RORE % falls into.


STU:UG2
66GF Score
AngioDynamics Inc STU:UG2
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics 5-Year RORE % Calculation

AngioDynamics's 5-Year RORE % for the quarter that ended in May. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.745--0.603 )/( -7.61-0 )
=-0.142/-7.61
=1.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in May. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of 1.87 mean?
AngioDynamics (STU:UG2) has a 5-Year RORE % of 1.87 as of May. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on AngioDynamics and its competitors. According to the industry distribution chart, AngioDynamics ranks #288 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 41%.
Is AngioDynamics' 5-Year RORE % too high?
AngioDynamics' current 5-Year RORE % is 1.87. Based on the distribution chart, AngioDynamics ranks #288 out of 702 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AngioDynamics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' 5-Year RORE % compare to NNNN and OSUR?
According to the Medical Devices & Instruments industry distribution chart, AngioDynamics ranks #288 out of 702 companies for 5-Year RORE %. This puts AngioDynamics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on AngioDynamics and its competitors. AngioDynamics's current 5-Year RORE % is 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
Based on GuruFocus' analysis, AngioDynamics (STU:UG2) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.32, compared to a current price of €11.80 — trading 41.8% above its estimated fair value. The current 5-Year RORE % is 1.87. AngioDynamics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For AngioDynamics (STU:UG2), the current 5-Year RORE % is 1.87 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (STU:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €11.80 is trading 41.8% above its estimated GF Value™ of €8.32. GuruFocus considers AngioDynamics to be Significantly Overvalued.

Key valuation signals for STU:UG2:

  • 5-Year RORE %: 1.87
  • GF Value™: €8.32 vs. price of €11.80 (41.8% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the STU:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
66GF Score

Get the complete analysis for STU:UG2

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.80
Price
€8.32
GF Value